BEAM Alliance has today released a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’!
- Antimicrobial resistance (AMR) is facing a market failure that has already jeopardised the development of valuable AMR products. Various key actionable areas can be considered to improve the landscape.
- Evaluation should capture the societal benefit of AMR products, while reimbursement framework should guarantee best medical care, informed by precise diagnosis and delivery of optimal preventative or curative therapy.
- Partially delinked market uptake support is required to de-risk the capital-intensive product launch, but interim incentives must also be designed to recoup investment made by the whole discovery and development value chain.
- As the cornerstone of the global medical infrastructure, antimicrobials should benefit from the support of other benefiting therapeutic areas.
- To allow for a sustainable management of the AMR crisis, incentives should assign priority to truly innovative and differentiated products.
- In the absence of immediate action, the whole AMR-focused SME landscape and key skill sets may be lost.
Full Memo available here